Xin Lang Cai Jing·2025-09-12 07:31Group 1 - The core point of the news is that Tiger Med's stock has experienced a decline, with a cumulative drop of 9.2% over the last four days, closing at 61.01 yuan per share on September 12, with a total market capitalization of 52.531 billion yuan [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, and other related services [1] - The company's main revenue sources include clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [1] Group 2 - Morgan Fund holds a position in Tiger Med through the Morgan CSI Innovative Drug Industry ETF (560900), which reduced its holdings by 3,000 shares in the second quarter, now holding 18,100 shares, accounting for 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million, with a year-to-date return of 40.82% and a one-year return of 60.71% [2] - The fund manager, Mao Shichao, has been in position for 5 years and 128 days, with the fund's best return during this period being 56.22% and the worst being -24.75% [3]